PRDS | Pardes Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1300 - 2.1810
52 Week Range	0.7500 - 3.67
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,150,077
Average Volume	509,687
Shares Outstanding	62,011,800
Market Cap	135,185,724
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-27

Valuation
Profitability
Growth
Health
P/E Ratio	-1.70
Forward P/E Ratio	N/A
EPS	-1.28
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	USA
Website	PRDS

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

PRDS's peers: PMCB, CSBR, ELYM, GNTA, HCWB, IOBT, IPA, IPHA, LUMO, PHAR, RLMD, STRO, STTK, TRDA, HLVX

*Chart delayed

Analyzing fundamentals for PRDS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PRDS Fundamentals page.

Watching at PRDS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PRDS Technicals page.